Given that the increase was approximately 1.24-fold, we further demonstrated the efficacy of our strategy by using the relative concentrations of Sunitinib to treat transforming growth factor-beta 1 (TGF-β1)-activated hepatic stellate cells LX2, the key fibrotic cell that drives liver fibrosis [4]. The gene discussed is TGFB1; the disease is Hepatic fibrosis.